Share on LinkedInShare on LinkedIn

ARTICLE · 20 JANUARY 2016

SIPO Shifts On Data Disclosure Requirement

AnJie Broad Law Firm
AnJie Broad Law Firm
Contributor
AnJie Broad Law Firm

AnJie Broad Law Firm

AnJie Broad is a full-service law firm with a wide range of practice areas. We are committed to...

View firm profile
Explore more from AnJie Broad Law Firm

According to the criticisms, this unique data requirement of SIPO for medical inventions, especially for compound inventions, is not in line with the patent practices in other major jurisdictions.

ChinaIntellectual Property

Article 26.3 of the Chinese Patent Law specifies a sufficient disclosure requirement: "the description shall set forth the invention or utility model in a manner sufficiently clear and complete so as to enable a person skilled in the relevant field of technology to carry it out." However, there was a great deal of controversy in Chinese patent practices concerning whether or not the State Intellectual Property Office (SIPO) had correctly interpreted this provision for medical inventions, especially the so-called "compound invention", which is an invention simply directed to a compound itself, not to the potential pharmaceutical usage of the compound.

SIPO had been heavily criticized for insisting that, for all medical inventions including compound inventions, some rather specific experimental data demonstrating the pharmaceutical usage of the invention must be included in the specification, and that no post-filing data is allowed to address the sufficient

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from